365 related articles for article (PubMed ID: 37298276)
1. Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease.
Lee HA; Kim HY
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298276
[TBL] [Abstract][Full Text] [Related]
2. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
Patel Chavez C; Cusi K; Kadiyala S
J Clin Endocrinol Metab; 2022 Jan; 107(1):29-38. PubMed ID: 34406410
[TBL] [Abstract][Full Text] [Related]
3. The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease.
Tsiampali C; Papaioannidou P; Goulas A; Polyzos SA
Expert Rev Clin Pharmacol; 2023; 16(11):1063-1072. PubMed ID: 37864548
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
[TBL] [Abstract][Full Text] [Related]
5. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Fang L; Li J; Zeng H; Liu J
Prim Care Diabetes; 2024 Jun; 18(3):268-276. PubMed ID: 38555202
[TBL] [Abstract][Full Text] [Related]
6. The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
Abdelmalek MF; Harrison SA; Sanyal AJ
Diabetes Obes Metab; 2024 Jun; 26(6):2001-2016. PubMed ID: 38511418
[TBL] [Abstract][Full Text] [Related]
7. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
Barritt AS; Marshman E; Noureddin M
Aliment Pharmacol Ther; 2022 Apr; 55(8):944-959. PubMed ID: 35266164
[TBL] [Abstract][Full Text] [Related]
8. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.
Chen Y; Xu YN; Ye CY; Feng WB; Zhou QT; Yang DH; Wang MW
Acta Pharmacol Sin; 2022 May; 43(5):1156-1166. PubMed ID: 34934197
[TBL] [Abstract][Full Text] [Related]
9. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
[TBL] [Abstract][Full Text] [Related]
10. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 receptor agonists in NAFLD.
Petit JM; Vergès B
Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials.
Gu Y; Sun L; He Y; Yang L; Deng C; Zhou R; Kong T; Zhang W; Chen Y; Li J; Shi J
Expert Rev Gastroenterol Hepatol; 2023 Mar; 17(3):273-282. PubMed ID: 36689199
[TBL] [Abstract][Full Text] [Related]
13. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists.
Goldenberg RM; Gilbert JD; Manjoo P; Pedersen SD; Woo VC; Lovshin JA
Obes Rev; 2024 Mar; 25(3):e13663. PubMed ID: 37968541
[TBL] [Abstract][Full Text] [Related]
14. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
15. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Romero-Gómez M; Lawitz E; Shankar RR; Chaudhri E; Liu J; Lam RLH; Kaufman KD; Engel SS;
J Hepatol; 2023 Oct; 79(4):888-897. PubMed ID: 37355043
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
[TBL] [Abstract][Full Text] [Related]
18. GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD.
Jiang H; Zang L
Curr Pharm Des; 2024; 30(2):100-114. PubMed ID: 38532322
[TBL] [Abstract][Full Text] [Related]
19. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.
Wang XC; Gusdon AM; Liu H; Qu S
World J Gastroenterol; 2014 Oct; 20(40):14821-30. PubMed ID: 25356042
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease.
Yabut JM; Drucker DJ
Endocr Rev; 2023 Jan; 44(1):14-32. PubMed ID: 35907261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]